Plant-derived Recombinant Human Serum Albumin Injection (HY1001 project) Clinical Trials Phase II Data Progress Report

Source:Posted by Themecurve| Time:2021-09-27| Hits:197

September 26th, China Health Ecology Organization (CHEO) was grandly held in Bo’ao. At the Pharmaceutical Innovation and Capital Market sub-forum of the China Pharmaceutical Innovation Ecological conference (CPIE), which is the one of the six core summits of CHEO, Professor Daichang Yang , President, General Manager and Chief Scientist of Wuhan Healthgen Biotechnology Corp, gave a detailed report on the technical advancement of the rice endosperm specific expression platform (OryzHiExp), and the series of bio-innovative biopharmaceuticals developed by this platform, represented by plant-derived recombinant human serum albumin injection (Project HY1001).    

 

Project HY1001 is undergoing the clinical trial phase II. As of the report date, the enrollment data showed that all of the designed clinical primary or secondary endpoints were reached, demonstrating the great safety and efficacy.            

 

During the conference, Healthgen Biotech’s technical platform and multiple projects have received extensive attention from many investors. Among them, Jointown Pharmaceutical Group Co., Ltd. and Yunnan Baiyao Group Co.,Ltd. showed strong interest and willingness to invest.

 

 

 

Author:Site editorEdit:Site editor
Share

Wuhan Healthgen Biotechnology Corp.

Tel. +86 027 59301891 Ext 8015

Fax. +86 027 59403931

E-mail cjing@oryzogen.com

268 Shendun 5th Road, East Lake High-Tech Development Zone, Wuhan, China 430020

Copyright ® Wuhan Healthgen Biotechnology Corp. All rights reserved. Terms and Conditions of Use
鄂ICP备12013293号-3